代謝パネル検査市場- 世界の産業規模、シェア、動向、機会、予測：分析物別、疾患別、最終用途別、地域別セグメント、競合、2020年～2030年

代謝パネル検査の世界市場規模は、2024年に124億1,000万米ドルとなり、2030年には215億6,000万米ドルに達すると予測され、予測期間中のCAGRは9.62%で成長すると予測されています。

世界的にヘルスケアシステムが早期診断と予防医療を優先しているため、市場は着実に拡大しています。包括的代謝パネル（CMP）検査は、腎臓や肝臓の機能、血糖値、電解質バランスに関する知見を提供する日常的な診断ツールとなっています。糖尿病、腎臓病、肝機能障害などの代謝異常の有病率の増加により、CMP検査は臨床診断に不可欠なものとなっています。さらに、人口の高齢化と日常的な健康モニタリングの重要性の高まりにより、CMP検査を受ける患者層が拡大しています。CMP検査は現在、入院・外来を問わず、健康診断の一環として定期的に実施されています。検査室の自動化やデジタルデータの統合などの技術的進歩により、検査の効率と精度が向上しています。個別化医療やポイントオブケア検査機器の人気が高まっており、特に緊急医療や遠隔地では、これらの診断がより身近なものとなり、市場全体の成長に寄与しています。

市場概要
予測期間	2026-2030
市場規模：2024年	124億1,000万米ドル
市場規模：2030年	215億6,000万米ドル
CAGR：2025年～2030年	9.62%
急成長セグメント	糖尿病
最大市場	北米

市場促進要因

慢性疾患および代謝性疾患の有病率の上昇

主な市場課題

高度診断機器の高コスト

主要市場動向

個別化・予防ヘルスケアへのシフト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の代謝パネル検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 分析物別（K+、Na+、Cl-、CO2、グルコース、BUN、クレアチニン、Ca++、アルブミン、総タンパク質、ALP、ALT、AST、総ビリルビン）
  • 疾患別（腎臓病、肝臓病、糖尿病、その他）
  • 最終用途別（研究室、PoC、PoC（機器））
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の代謝パネル検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の代謝パネル検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の代謝パネル検査市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の代謝パネル検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの代謝パネル検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Abbott Laboratories
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings Limited
• Sonic Healthcare Limited
• Unipath Specialty Laboratory Limited
• SYNLAB International GmbH
• ARUP Laboratories
• Genoptix, Inc.
• Nova Medical, Inc.
• Mindray Medical International Limited

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Metabolic Panel Testing Market was valued at USD 12.41 billion in 2024 and is projected to reach USD 21.56 billion by 2030, growing at a CAGR of 9.62% during the forecast period. The market is expanding steadily as healthcare systems globally prioritize early diagnosis and preventive healthcare. Comprehensive Metabolic Panel (CMP) testing has become a routine diagnostic tool, offering insights into kidney and liver function, blood glucose, and electrolyte balance. The increasing prevalence of metabolic disorders such as diabetes, kidney disease, and liver dysfunction has made CMP tests vital in clinical diagnostics. Additionally, an aging population and the rising importance of routine health monitoring are enlarging the patient base for these tests. CMP testing is now a regular part of wellness checkups in both inpatient and outpatient settings. Technological advancements, including laboratory automation and digital data integration, are enhancing testing efficiency and accuracy. The rising popularity of personalized medicine and point-of-care testing devices, particularly in urgent care and remote areas, is making these diagnostics more accessible and contributing to overall market growth.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 12.41 Billion
Market Size 2030	USD 21.56 Billion
CAGR 2025-2030	9.62%
Fastest Growing Segment	Diabetes
Largest Market	North America

Key Market Drivers

Rising Prevalence of Chronic and Metabolic Disorders

The growing incidence of chronic and metabolic disorders is a major driver of the Global Metabolic Panel Testing Market. Noncommunicable diseases (NCDs) such as cardiovascular conditions, cancer, chronic respiratory diseases, and diabetes are now the leading causes of mortality globally. In 2021, NCDs were responsible for 75% of all deaths worldwide, with cardiovascular diseases causing 19 million deaths, cancers 10 million, chronic respiratory diseases 4 million, and diabetes over 2 million. Metabolic disorders like hypertension, high blood sugar, and elevated lipid levels are critical risk factors for these conditions. A global meta-analysis involving 28 million individuals found that the prevalence of metabolic syndrome ranges from 12.5% to 31.4%, with higher rates in the Eastern Mediterranean and the Americas. Many of these conditions remain undiagnosed until complications arise, highlighting the need for regular metabolic screening through CMP tests for early detection and preventive intervention.

Key Market Challenges

High Cost of Advanced Diagnostic Equipment

The cost associated with acquiring and operating advanced diagnostic equipment remains a key challenge in the Global Metabolic Panel Testing Market. Accurate CMP testing relies on sophisticated analyzers capable of evaluating multiple biomarkers, including glucose levels, enzymes, and electrolytes. These instruments involve substantial capital investment and require ongoing expenditure on maintenance and consumables. For smaller or resource-limited healthcare facilities, especially in developing regions, such expenses can be prohibitive. Smaller diagnostic laboratories may be unable to justify or afford the cost, leading to limited test offerings or dependence on outdated systems with lower accuracy and efficiency. This creates disparities in access to reliable diagnostics across different regions and facility types, posing a challenge to universal healthcare goals.

Key Market Trends

Shift Toward Personalized and Preventive Healthcare

A prominent trend influencing the Global Metabolic Panel Testing Market is the transition toward personalized and preventive healthcare. As healthcare providers increasingly focus on early detection and tailored treatment strategies, CMP testing plays an essential role in identifying metabolic imbalances before clinical symptoms emerge. The ability to detect early signs of conditions such as diabetes and hypertension allows for customized treatment planning, enhancing patient care outcomes. Advances in genomics are further supporting this shift, as genetic profiling is combined with CMP results to develop individualized health management approaches. This integration is fostering a proactive model of care, with the emphasis shifting from disease treatment to early intervention and disease prevention.

Key Market Players

• Abbott Laboratories
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings Limited
• Sonic Healthcare Limited
• Unipath Specialty Laboratory Limited
• SYNLAB International GmbH
• ARUP Laboratories
• Genoptix, Inc.
• Nova Medical, Inc.
• Mindray Medical International Limited

Report Scope:

In this report, the Global Metabolic Panel Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolic Panel Testing Market, By Analytes:

• K+
• Na+
• Cl-
• CO2
• Glucose
• BUN
• Creatinine
• Ca++
• Albumin
• Total protein
• ALP
• ALT
• AST
• Total bilirubin

Metabolic Panel Testing Market, By Disease:

• Kidney Disease
• Liver Disease
• Diabetes
• Others

Metabolic Panel Testing Market, By End Use:

• Laboratory
• PoC
• PoC (Instruments)

Metabolic Panel Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metabolic Panel Testing Market.

Available Customizations:

Global Metabolic Panel Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Metabolic Panel Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Analytes (K+, Na+, Cl-, CO2, Glucose, BUN, Creatinine, Ca++, Albumin, Total protein, ALP, ALT, AST, Total bilirubin)
  • 5.2.2. By Disease (Kidney Disease, Liver Disease, Diabetes, Others)
  • 5.2.3. By End Use (Laboratory, PoC, PoC (Instruments))
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Metabolic Panel Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Analytes
  • 6.2.2. By Disease
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Metabolic Panel Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Analytes
      • 6.3.1.2.2. By Disease
      • 6.3.1.2.3. By End Use
  • 6.3.2. Mexico Metabolic Panel Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Analytes
      • 6.3.2.2.2. By Disease
      • 6.3.2.2.3. By End Use
  • 6.3.3. Canada Metabolic Panel Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Analytes
      • 6.3.3.2.2. By Disease
      • 6.3.3.2.3. By End Use

7. Europe Metabolic Panel Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Analytes
  • 7.2.2. By Disease
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Metabolic Panel Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Analytes
      • 7.3.1.2.2. By Disease
      • 7.3.1.2.3. By End Use
  • 7.3.2. Germany Metabolic Panel Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Analytes
      • 7.3.2.2.2. By Disease
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Metabolic Panel Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Analytes
      • 7.3.3.2.2. By Disease
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Metabolic Panel Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Analytes
      • 7.3.4.2.2. By Disease
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Metabolic Panel Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Analytes
      • 7.3.5.2.2. By Disease
      • 7.3.5.2.3. By End Use

8. Asia-Pacific Metabolic Panel Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Analytes
  • 8.2.2. By Disease
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Metabolic Panel Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Analytes
      • 8.3.1.2.2. By Disease
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Metabolic Panel Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Analytes
      • 8.3.2.2.2. By Disease
      • 8.3.2.2.3. By End Use
  • 8.3.3. South Korea Metabolic Panel Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Analytes
      • 8.3.3.2.2. By Disease
      • 8.3.3.2.3. By End Use
  • 8.3.4. Japan Metabolic Panel Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Analytes
      • 8.3.4.2.2. By Disease
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Metabolic Panel Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Analytes
      • 8.3.5.2.2. By Disease
      • 8.3.5.2.3. By End Use

9. South America Metabolic Panel Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Analytes
  • 9.2.2. By Disease
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Metabolic Panel Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Analytes
      • 9.3.1.2.2. By Disease
      • 9.3.1.2.3. By End Use
  • 9.3.2. Argentina Metabolic Panel Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Analytes
      • 9.3.2.2.2. By Disease
      • 9.3.2.2.3. By End Use
  • 9.3.3. Colombia Metabolic Panel Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Analytes
      • 9.3.3.2.2. By Disease
      • 9.3.3.2.3. By End Use

10. Middle East and Africa Metabolic Panel Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Analytes
  • 10.2.2. By Disease
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Metabolic Panel Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Analytes
      • 10.3.1.2.2. By Disease
      • 10.3.1.2.3. By End Use
  • 10.3.2. Saudi Arabia Metabolic Panel Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Analytes
      • 10.3.2.2.2. By Disease
      • 10.3.2.2.3. By End Use
  • 10.3.3. UAE Metabolic Panel Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Analytes
      • 10.3.3.2.2. By Disease
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Abbott Laboratories
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Quest Diagnostics Incorporated
• 14.3. Laboratory Corporation of America Holdings Limited
• 14.4. Sonic Healthcare Limited
• 14.5. Unipath Specialty Laboratory Limited
• 14.6. SYNLAB International GmbH
• 14.7. ARUP Laboratories
• 14.8. Genoptix, Inc.
• 14.9. Nova Medical, Inc.
• 14.10. Mindray Medical International Limited

15. Strategic Recommendations

16. About Us & Disclaimer